Clinical trial · Interventional
Safety and Efficiency of IRE Plus γδ T Cell Against Locally Advanced Pancreatic Cancer
NCT03180437CI-TRIAL-00048025completedPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this study, effects of γδT cells on human Pancreatic Cancer in combination with tumor reducing surgery, for example IRE going to be investigated.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| IRE plus γδ T cells | Biological | — | UNRESOLVED |
| IRE surgery | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Group A
- description
- In this group, the patients will receive IRE surgery to control the local tumor under CT .
- interventionNames
- Procedure: IRE surgery
- type
- EXPERIMENTAL
- label
- Group B
- description
- In this group, the patients will receive multiple high-activity γδ T cell immunotherapies and IRE surgery
- interventionNames
- Biological: IRE plus γδ T cells
Primary outcomes (2)
- measure
- PFS
- timeFrame
- 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. age: \>18 years 2. participants older than 18 years with either LAPC according to the American Joint Committee on Cancer (AJCC) criteria or isolated local recurrence with a maximum tumor diameter of 5 cm were considered eligible after pathologic confirmation 3. will receive IRE, gd Tcells 4. life expectancy: more than 3 months 5. ability to understand the study protocol and a willingness to sign a written informed consent document 6. adequate liver and renal function were required 7. intolerant or refused to chemotherapy or to chemotherapy Exclusion Criteria: 1. patients with other kinds of cancer 2. history of coagulation disorders or anemia 3. heart disease and diabetes 4. history of epilepsy, severe coronary disease, a history of level 3 hypertension，myelosuppression, autoimmune disease 5. a performance status score of \>2
References
Publications (1)
- DERIVEDLin M, Zhang X, Liang S, Luo H, Alnaggar M, Liu A, Yin Z, Chen J, Niu L, Jiang Y. Irreversible electroporation plus allogenic Vgamma9Vdelta2 T cells enhances antitumor effect for locally advanced pancreatic cancer patients. Signal Transduct Target Ther. 2020 Oct 23;5(1):215. doi: 10.1038/s41392-020-00260-1. PMID 33093457